Joon Hyeok Lee

Joon Hyeok Lee

Auto-generated profile, based on publicly available information

Joon Hyeok Lee

Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2018 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Open access
PDF file
JLJeong-Hoon Lee
Jeong-Hoon Lee
JLJoon Hyeok Lee
Joon Hyeok Lee
YLYoung-Suk Lim
Young-Suk Lim
JYJong Eun Yeon
Jong Eun Yeon
TSTae-Jin Song
Tae-Jin Song
JYJung-Hwan Yoon
Jung-Hwan Yoon
Our earlier multicenter randomized controlled trial showed that adjuvant immunotherapy with cytokine-induced killer (CIK) cells resulted in longer recurrence-free survival (RFS) and overall survival (OS) as well in patients who received curative treatment for hepatocellular carcinoma (HCC). In the present study, we determined if the efficacy of CIK cell therapy continued after end of repeated CIK cell injections. We performed a follow-up study of our preceding trial. We included 226 patients: 114 patients in the immunotherapy group (injection of 6.4 × 109 CIK cells, 16 times during 60 weeks) and 112 patients in the control group (no treatment) after potentially curative treatment for HCC. In total, 162 patients (89 of the immunotherapy group and 73 of controls) underwent an extended follow-up for 60 months after randomization of the last patient. The primary endpoint was RFS, and secondary endpoints included OS. During follow-up time of median 68.5 months (interquartile range 45.0–82.2 months), the immunotherapy group continued to show a significantly lower risk of recurrence or death [hazard ratio (HR) 0.67; 95% confidence interval (CI) 0.48–0.94; P = 0.009 by one-sided log-rank test]. At 5 years, RFS rate was 44.8% in the immunotherapy group and 33.1% in the control group. The risk of all-cause death was also lower in the immunotherapy group compared to the control group (HR 0.33; 95% CI 0.15–0.76; P = 0.006). In patients who received curative treatment for HCC, the significant improvement in RFS and OS as a result of adjuvant CIK cell immunotherapy lasted over 5 years without boosting.

1 January 2020 in Annals of Surgical Treatment and Research
Verified
Journal Article
Open access
PDF file
JOJoo Hyun Oh
Joo Hyun Oh
DSDong Hyun Sinn
Dong Hyun Sinn
GCGyu-Seong Choi
Gyu-Seong Choi
JKJong Man Kim
Jong Man Kim
JJJae-Won Joh
Jae-Won Joh
MCMoon Seok Choi
Moon Seok Choi
Oh JH, et al. Ann Surg Treat Res. 2020 Oct;99(4):238-246. https://doi.org/10.4174/astr.2020.99.4.238

30 September 2012 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
DSDong Hyun Sinn
Dong Hyun Sinn
MCMoon Seok Choi
Moon Seok Choi
GGGeum-Youn Gwak
Geum-Youn Gwak
YPYong-Han Paik
Yong-Han Paik
JLJoon Hyeok Lee
Joon Hyeok Lee
BYByung Chul Yoo
Byung Chul Yoo

30 June 2021 in Hepatology
Verified
Journal Article
Closed access
PDF file
YPYewan Park
Yewan Park
DSDong Hyun Sinn
Dong Hyun Sinn
JOJoo Hyun Oh
Joo Hyun Oh
MGMyung Ji Goh
Myung Ji Goh
KKKyunga Kim
Kyunga Kim
GGGeum‐Youn Gwak
Geum‐Youn Gwak

31 March 2015 in Liver International
Verified
Journal Article
Closed access
PDF file
JLJi Yun Lee
Ji Yun Lee
SLSung Hee Lim
Sung Hee Lim
MLMin‐Young Lee
Min‐Young Lee
HKHaesu Kim
Haesu Kim
DSDong Hyun Sinn
Dong Hyun Sinn
KKKihyun Kim
Kihyun Kim

17 August 2010 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
DSDong Hyun Sinn
Dong Hyun Sinn
SSSu Rin Shin
Su Rin Shin
JKJae Sook Kil
Jae Sook Kil
JKJeong Kim
Jeong Kim
GGGeum-Youn Gwak
Geum-Youn Gwak
SPSeung Woon Paik
Seung Woon Paik